Eli Lilly and Company has successful completed acquisition of Centessa Pharmaceuticals plc.
Centessa is a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for the treatment of narcolepsy and potentially other sleep-wake disorders.
‘The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling’, said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. ‘For people living with narcolepsy, that disruption is severe and life-altering. Orexin’s reach extends further to diseases impacted by disrupted sleep, and so does the unmet need. Centessa has built a clinical portfolio with the depth to explore both, and Lilly intends to pursue that potential with urgency.’
